SCHEMBL5138010

SCHEMBL5138010

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(O)c([N+](=O)[O-])c1)CC1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
POLB P06746 1/20 0.36
BCHE P06276 2/20 0.34
HDAC1 Q13547 1/20 0.34
ACHE P22303 1/20 0.34
ABCC1 P33527 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.34
NR1D1 P20393 1/20 0.33
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
AVPR1B P47901 1/20 0.32
UBE2M P61081 1/20 0.32
DCUN1D1 Q96GG9 1/20 0.32
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072326 0.94 C5AR1 (0.41) C5AR1BCHEHDAC1ACHENR1D1
SCHEMBL4763715 0.88 C5AR1 (0.46) C5AR1BCHEHDAC1ACHEALDH1A1
SCHEMBL5137739 0.88 C5AR1 (0.43) C5AR1POLBABCC1ABCG2ALDH1A1
SCHEMBL5135644 0.88 POLB (0.43) C5AR1POLBBCHEHDAC1ABCC1
SCHEMBL5135268 0.87 C5AR1 (0.42) C5AR1BCHEHDAC1ACHEAVPR1B
SCHEMBL651431 0.87 C5AR1 (0.43) C5AR1BCHEHDAC1ACHEALDH1A1
SCHEMBL5135294 0.86 C5AR1 (0.44) C5AR1BCHEHDAC1ACHEABCC1
SCHEMBL1913025 0.85 C5AR1 (0.41) C5AR1BCHEHDAC1ACHEALDH1A1
SCHEMBL5135713 0.84 C5AR1 (0.44) C5AR1HDAC1ABCC1ALDH1A1KDM4E
SCHEMBL5137864 0.84 C5AR1 (0.44) C5AR1BCHEHDAC1ABCC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed